Podcasts about Heart failure

Cardiologist and electrophysiologist Dr. Gregory Marcus, chair of the American Heart Association scientific statement writing group, reveals evidence on coffee/caffeine and cardiovascular health. He discusses how earlier assumptions that caffeine triggers arrhythmias are complicated by genetics, individual risk factors, and mostly observational research. Marcus reviews randomized and observational findings: the CRAVE trial showed no increase in premature atrial contractions but more premature ventricular contractions on coffee days; a trial in post-cardioversion patients found less atrial fibrillation with daily coffee. Observational data suggest lower risks of type 2 diabetes, heart attack, stroke, and AFib among coffee drinkers, while heart failure risk may be lower at low intake but higher around 4–5 drinks/day. He cautions against extrapolating benefits to energy drinks, discusses additives like sugar, touches on alcohol, cannabis, Mediterranean/DASH diets, pollution, and evolving AFib treatments, wearables, and pacing/ablation technologies.

Interview: Dr. Ozoemena: Welcome back to our community health podcast, where we discuss important health topics in ways everybody can understand. Today we will be talking about Heart Failure. Many people have heard this term before, but it often causes fear and confusion. Here to talk about this important topic is Dr. Ken Nweke, a resident at our program, and he will be discussing this topic in Pidgin English so that some people in our community can understand it. Dr. Nweke, welcome to the program.  Dr. Nweke: Thank you very much. I happy make we discuss dis very important mata today.  Dr. Ozoemena: Let's start with the basics. What exactly is heart failure?  Dr. Nweke: First make we understand one thing. The heart na our generator. Just like generator dey provide light for house, the heart dey pump blood carry oxygen and nutrients go every part of the body. Every organ for body depend on the heart to survive. When person get heart failure, e no mean say the heart don stop work. E mean say the heart no dey pump enough blood and oxygen reach the body the as e suppose. The generator still dey run, but e no get enough power again. That struggle fit make different parts of the body begin show signs say wahala dey.  Dr. Ozoemena: What are some of the common causes of heart failure?  Dr. Nweke: Many things fit cause heart failure. One common cause na high blood pressure wey person don get for long time. If blood pressure high for many years, the heart go dey work harder pass normal every day. After some time, the heart fit begin weak. Heart attack fit also damage the heart muscle. When blood no reach part of the heart muscle, dat part fit damage and the heart no go pump blood well again. Sugar disease wey oyibo dey call diabetes also fit cause am Kidney disease fit contribute too. Some people get heart valve problems. Some oda people fit get heart problems from when dem born dem. People wey dey drink alcohol like water or people wey dey smoke fit develop am. Certain yama yama disease or infections fit affect the heart muscle. And for some families, heart problems fit run from generation to generation.  Dr. Ozoemena: What symptoms should people watch out for?  Dr. Nweke: One big sign na shortness of breath. At first, person fit notice am when e dey walk fast, climb stairs, or do heavy work. As the condition worsen, breathing fit become difficult even when person just dey rest. Some people go wake up for night because dem no fit breathe well. Some people go need plenty pillows before dem fit sleep well. Leg, ankle and foot fit swell. Water fit gather for body. Some people go notice say dem gain weight because water don full for body. Person fit tire easily. Things wey dem fit do before without problem fit become difficult. Some people fit get cough wey no gree go. Others fit notice swelling for belle because fluid don gather. Heart fit dey beat fast or anyhow.  Dr. Ozoemena: When should someone seek medical attention?  Dr. Nweke: If person dey notice shortness of breath wey no dey improve, swelling for leg, tiredness wey no dey normal, cough wey no gree stop, or weight gain wey sudden, e dey very important make e go see doctor. If person suddenly no fit breathe, get serious chest pain, faint, or collapse, dat one fit be emergency. Make dem go hospital immediately.  Dr. Ozoemena: How do doctors find out if someone has heart failure?  Dr. Nweke: Doctor go first ask plenty questions make dem sabi wetin b d kasala - doctors dey call history taking. Doctor go examine the patient. Dem go check blood pressure. Dem fit listen to the heart and lungs with stethoscope. Dem fit check for swelling for leg and foot. Blood tests fit help. Some blood tests fit show whether the heart dey under stress. Chest X-ray fit show whether fluid don gather for the lungs. EKG fit help weda electricals for d heart dey ok. One very important test na echocardiogram. Na ultrasound of the heart. E fit show say d heart don weak as e dey pump blood. e dey also check weda d heart valves dey ok. Heart valves na small small doors wey dey for heart wey dey open or close as the heart dey pump. Sometimes doctor fit request other tests depending on the situation.  Dr. Ozoemena: Can heart failure be treated?  Dr. Nweke: Yes or Better treatment dey. Although some cases no fit cure completely, treatment fit help people make dem live longer and feel better. We get medicines wey fit help the heart work better. Some medicines help remove extra water from the body. Some medicines help reduce the work wey the heart dey do. Others fit help protect the heart make e no weak For some people, doctor fit recommend special devices or surgery depending on the cause. But medicine no be the only thing. Lifestyle changes important too.  Dr. Ozoemena: What lifestyle changes can help?  Dr. Nweke: Person wey get heart failure suppose reduce salt for food. Too much salt fit make water gather for body. Dem suppose take medicines exactly the way doctor prescribe. Regular exercise fit help if doctor say e safe. Make dem avoid smoking. Too much alcohol no good. Try maintain healthy body weight. And make person keep all clinic appointments so doctor fit monitor the condition.  Dr. Ozoemena: Can heart failure be prevented?  Dr. Nweke: For many people, yes. make we control high blood pressure - taking medication, go see your doctor regularly Control sugar disease/diabetes. Make we try dey exercise regularly. Make we dey eat healthy food. Reduce salt for food. Avoid smoking. Avoid too much alcohol. Keep healthy weight. And go for regular medical checkup. Many times, if we control these risk factors early, we fit reduce the chance of developing heart failure. Dr. Ozoemena: Before we close, what would you like everyone listening to remember?  Dr. Nweke: Remember say heart failure no mean say the heart don stop work. The heart still dey work, but e dey struggle. Think of am like generator wey still dey run but im light weak, e no dey carry wetin e dey carry before. If you notice shortness of breath, swelling for leg, unusual tiredness, cough wey no gree go, or sudden weight gain, make you go see doctor. No wait until the condition become serious.  Dr. Ozoemena: Thank you, Dr. Nweke. And thank you to everyone listening today. Remember, heart na our generator. Take care of am. Until next time, stay healthy and stay informed Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!  _____________________ References: Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

Join us as we explore the rapidly evolving world of pediatric heart failure and ventricular assist devices. Through conversations with leading experts, we discuss the latest innovations, emerging research, and real-world challenges while gaining insights into where the field is headed and what the future holds for children with advanced heart failure. Hosts: Chris Knoll, MD (Phoenix Children's) Guests: Christina J. VanderPluym, MD (Boston Children's), Jonathan B. Edelson, MD (Children's Hospital of Philadelphia), Joseph Spinner, MD (Texas Children's) Executive Producer: Chris Knoll, MD (Phoenix Children's) Sponsor: Rady Children's Heart Institute

Heart failure patients are often living in a black box – not knowing how they're really doing until they end up in the ER. StartUp Health community member Sean Matsuoka, CEO & Co-founder of General Prognostics (GPx) ( https://www.startuphealth.com/gpx ...

This week's topics include caffeine's impact on CVD, antihistamines and atopic dermatitis, a community designed diet for heart failure, and e-cigarettes after smoking cessation.

Recorded at EHRA 2026, this episode of The Lead features host Melissa Middeldorp, MPH, PhD, FHRS, in conversation with Sana Al-Khatib, MD, MHS, FHRS, and Wei Hua, MD, FHRS, about the journal article, Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial. Together, they discuss the findings of the PhysioSync-HF randomized clinical trial, comparing conduction system pacing with biventricular pacing in patients with heart failure and exploring the potential implications for clinical practice.   Learning Objectives: Review the design and key findings of the PhysioSync-HF randomized clinical trial comparing conduction system pacing and biventricular pacing in patients with heart failure. Discuss the differences between conduction system pacing and biventricular pacing as evaluated in the PhysioSync-HF trial. Examine the potential clinical implications of the trial findings for pacing strategies in patients with heart failure.   Host: Melissa Middeldorp, MPH, PhD, FHRS Guests: Sana Al-Khatib, MD, MHS, FHRS and Wei Hua, MD, FHRS   Disclosures: M. Middeldorp ·      No relevant disclosures   S. Al-Khatib ·      Other Financial Relationship: American Heart Association   W. Hua ·      No relevant disclosures

Commentary by Dr. Cheng Liu.

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung Center Cardiologist Dr. Geurys Rojas-Marte discuss the breakthroughs in heart failure treatment.

Heart failure remains one of the leading causes of hospitalization among older adults worldwide. During episodes of acute decompensated heart failure (ADHF), excess fluid builds up in the lungs and body, making breathing difficult and increasing the risk of serious complications. Although intravenous loop diuretics such as furosemide are the standard treatment for relieving congestion, many patients continue to experience persistent inflammation, ongoing cardiac remodeling, and worsening heart function despite therapy. A research paper published in Volume 18 of Aging titled “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF),” investigated whether combining intravenous furosemide with small volumes of hypertonic saline solution (HSS) could improve biological markers associated with heart failure compared with furosemide alone. Full blog post - https://aging-us.org/2026/08/hypertonic-saline-plus-furosemide-improves-heart-failure-biomarkers-in-randomized-trial/ DOI - https://doi.org/10.18632/aging.206364 Corresponding author - Antonino Tuttolomondo - bruno.tuttolomondo@unipa.it Abstract video - https://www.youtube.com/watch?v=EG65XlcDJ3U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206364 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, heart failure, acute decompensated heart failure, furosemide, hypertonic saline solution To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In 11,409 adults with CKD and no prior heart failure, three standard ECG features independently predicted new-onset HF hospitalization. The findings support routine ECG as a low-cost adjunct to existing HF risk assessment in CKD.

CardioNerds Dr. Rohit Nathani, Dr. Atefeh Ghorbanzadeh, and Dr. Mariam Riad, discuss Obesity-related Heart Failure with Preserved Ejection Fraction (HFpEF) with Dr. John Ostrominski.  This episode was produced as part of the CardioNerds Academy curriculum by House Jones under the guidance of House Chief, Dr. Mariam Riad and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This episode highlights the diverse clinical phenotypes and complex, multifaceted pathophysiology of HFpEF. We take a deep dive into the therapeutic advances that represent paradigm shift in metabolic modulation aimed at improving outcomes in patients with HFpEF and metabolic syndrome. Audio editing by CardioNerds intern Pacey Wetstein. Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls HFpEF is a constellation of symptoms often with different underlying pathophenotypes; cardiometabolic type is rising in incidence. Diagnosis is predominantly based on the clinical scenario along with supporting evidence from imaging modalities such as echocardiogram, cardiac MRI, and right heart catheterization. Cardiometabolic HFpEF is a complex syndrome characterized by dysregulated lipid metabolism, systemic inflammation, and hemodynamic abnormalities, all of which contribute to exercise intolerance and frailty. Lifestyle interventions, comorbidities management, and HFpEF therapeutics go hand in hand for comprehensive HFpEF care and offer opportunities for multispecialty collaboration to achieve optimal patient outcomes. References Ostrominski, J, Højbjerg Lassen, M, Butt, J. et al. Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. JACC. 2025 Nov, 86 (20) 1760–1777.https://doi.org/10.1016/j.jacc.2025.08.012  Packer, M. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. JACC. 2025 Oct, 86 (16) 1269–1373.https://doi.org/10.1016/j.jacc.2025.06.055 Ahmed, N., Dalmasso, C., Turner, M.B. et al. From fat to filter: the effect of adipose tissue-derived signals on kidney function. Nat Rev Nephrol 21, 417–434 (2025). https://doi.org/10.1038/s41581-025-00950-5 Alicic, R.Z., Neumiller, J.J. & Tuttle, K.R. GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease. Nat Rev Nephrol 22, 265–282 (2026). https://doi.org/10.1038/s41581-025-01036-y Ostrominski, J, Harrington, J, Claggett, B. et al. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. JACC. 2025 Nov, 86 (20) 1781–1801.https://doi.org/10.1016/j.jacc.2025.08.039

Interview with Lauren A. Eberly, MD, MPH author of MUTTON -HF (Medically Utilized Tailored Traditional foods to Optimize Nutrition in Heart Failure): A Randomized Trial of an Indigenous Food is Medicine Intervention and Kurt Hager, MD author of Medically Tailored Meals and Heart Failure: A New Benchmark in Care. Hosted by Eve Rittenberg, MD Related Content: An Indigenous Food Is Medicine Intervention Lessons From a Community-Designed Meal Program for Heart Failure

Interview with Lauren A. Eberly, MD, MPH author of MUTTON -HF (Medically Utilized Tailored Traditional foods to Optimize Nutrition in Heart Failure): A Randomized Trial of an Indigenous Food is Medicine Intervention and Kurt Hager, MD author of Medically Tailored Meals and Heart Failure: A New Benchmark in Care. Hosted by Eve Rittenberg, MD Related Content: An Indigenous Food Is Medicine Intervention Lessons From a Community-Designed Meal Program for Heart Failure

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Gain expert insights on how best to implement GDMT for your patients in the transition from hospitalization to post-discharge. Credit available for this activity expires: 7/22/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/when-and-how-should-i-optimize-heart-failure-treatments-my-2026a1000ngg?ecd=bdc_podcast_libsyn_mscpedu

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden cardiac death, heart failure definitions updated, and a dumb decision by NICE in the UK are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Antiplatelet Therapy After Stenting DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 HOST-EXAM Trial at 2 years https://pubmed.ncbi.nlm.nih.gov/34010616/ HOST-EXAM Trial at 10 years 10.1016/S0140-6736(26)00422-8 External Link Nick Kurzen on X https://x.com/ncurzen/status/2077676739463922151 II Aspirin Proves Its Mettle After Hip and Knee Replacement EPCAT III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 CRISTAL Trial https://jamanetwork.com/journals/jama/fullarticle/2795528 III New (and old) Knowledge in Sudden Cardiac Death Sudden Cardiac Death and its Relation to Cardiac Disease at Autopsy https://doi.org/10.1016/j.jacc.2026.01.029 Sudden Cardiac Death Due to MI With Obstructive and Nonobstructive Coronary Arteries https://doi.org/10.1016/j.jacc.2026.01.030 Frequency of Sudden Cardiac Death and Profiles of Risk https://www.ajconline.org/article/S0002-9149(97)00477-3/fulltext IV Heart Failure Diagnosis AHA/ACC/ESC/WHF Expert Consensus Document http://jacc.org/doi/10.1016/j.jacc.2026.05.036 V NICE Makes a Dumb Decision NICE Recommends New Nonsteroidal MRA for Heart Failure https://www.medscape.com/viewarticle/nice-recommends-new-nonsteroidal-mra-heart-failure-2026a1000nzv You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this episode, Faraz Ahmad, MD, Associate Director at the Center for Artificial Intelligence, and Jonathan Hourmozdi, MD, Heart Failure and Heart Transplantation at Northwestern Medicine Bluhm Cardiovascular Institute, discuss how AI is improving heart failure diagnosis, care delivery, and patient engagement while emphasizing the importance of responsible implementation and governance. They also share their vision for an AI-powered future that reduces administrative burden, strengthens clinician-patient relationships, and expands access to high-quality cardiovascular care.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Dr. Quentin R. Youmans, Heart Failure and Heart Transplant Cardiologist, Northwestern Medicine, joins John Williams to talk about heart health, why he encourages patients to start small when on the path to better heart health, why it’s important to bring heart health screenings into the community, what you should know about the early signs of […]

Dr. Quentin R. Youmans, Heart Failure and Heart Transplant Cardiologist, Northwestern Medicine, joins John Williams to talk about heart health, why he encourages patients to start small when on the path to better heart health, why it’s important to bring heart health screenings into the community, what you should know about the early signs of […]

Dr. Quentin R. Youmans, Heart Failure and Heart Transplant Cardiologist, Northwestern Medicine, joins John Williams to talk about heart health, why he encourages patients to start small when on the path to better heart health, why it’s important to bring heart health screenings into the community, what you should know about the early signs of […]

❤️ New JACC statement, big clinical reset: the 2026 Second Universal Definition of Heart Failure moves us beyond rigid EF cutoffs toward a more useful bedside framework—define the syndrome, identify the stage, seek the cause, respect geography and social context, and follow the trajectory. The key message: improved EF is not "cured HF," and pre-HF is a prevention window hiding in plain sight. For clinicians: less "What's the EF?" and more "What's the cause, stage, trajectory, and context?"

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Heart Failure and Hypertension.Welcome to the Hypertension Resistant to Treatment Podcast, the #1 Hypertension Podcast in the world, with listeners from more than 152 countries who depend on our content. We are your primary resource for obtaining straightforward, practical, evidence-based information about high blood pressure management, regardless of your situation as a patient, healthcare provider, or family member. High blood pressure isn't always simple. The condition known as resistant hypertension affects many people who have high blood pressure that does not respond to medication or lifestyle changes. The medical field identifies treatment-resistant hypertension as a demanding yet vital medical condition that doctors encounter in their practice. The Hypertension Resistant to Treatment Podcast, website, and YouTube channel highlight the most challenging cases because these individuals have attempted multiple solutions without achieving any resolution. This podcast is here for them, but also for anyone touched by high blood pressure. Whether you're just starting your journey with prehypertension, you're living with long-standing hypertension, or you're a provider searching for better strategies to help your patients.The right place exists for those seeking answers, motivation, and success tools. The podcast Hypertension Resistant to Treatment presents blood pressure information in an easy-to-understand format that helps people control their condition. The Hypertension Resistant to Treatment podcast is hosted by Dr. Tonya Breaux-Shropshire, PhD, DNP, MPH, FNP-BC. Send us Fan Mail Support the showSupport the podcast by subscribing using this link: click here. We appreciate your support, thank you! Log your blood pressure and share with your provider (click here). Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research.Royalty-free music: Turn on My Swag 2 Epidemic Sound****Disclaimer: This podcast is for educational purposes only and is not medical advice. Always consult your own healthcare provider about your health. The views shared are those of the host and guests, and do not represent any other organization.”

The Central Role of Cardiac MRI in the Management of Heart Failure and Cardiomyopathy Patients   Guest: Gosia Wamil, M.D., Ph.D. Host: Malcolm R. Bell, M.D.   Cardiac MRI is now central to heart failure care, moving beyond imaging to guide diagnosis and treatment. It distinguishes disease causes, identifies fibrosis and scar, and uncovers specific conditions in both HFrEF and HFpEF. By providing prognostic markers, it helps tailor therapies and improve outcomes—delivering the right treatment at the right time. In this episode of "Interviews With the Experts," Dr. Malcolm Bell interviews Dr. Gosia Wamil from Mayo Clinic London practice on the role of cardiac MRI in practice.   Topics Discussed: When does CMR change the management decision? CMR findings Which CMR biomarkers truly predict outcomes—and how should clinicians act on them? From echo-first to CMR-led pathways: what should every HF service implement now?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 14-January-2026  

──────────────────────────────────────── [00:05:00] Hegseth Quotes Psalm 144 as God's Blessing for War — Knight: David Prayed Before Every Battle and Never Assumed God Was With Him David used the Urim and Thummim to ask God's will before war. Hegseth has no such instrument and no declaration of war from God or Congress. ──────────────────────────────────────── [00:15:00] Dispensationalism's Core Error: Treating the Shadow as Greater Than the Reality It Points To Knight: Hebrews was written to people returning to the shadow of Judaism rather than the substance in Christ — Hegseth and Huckabee are the Judaizers of Galatians, replacing Christ with a political state. ──────────────────────────────────────── [00:28:00] Nick Kupper: The COVID Shot Was Never Legally Approved — Pfizer Didn't Manufacture an Approved Version Until January 2022 DOD admitted in Kupper's lawsuit that nothing was fully approved until June 2022 — by which time the Air Force had already kicked people out for the unlawfully mandated product. ──────────────────────────────────────── [00:38:00] Kupper's Base Immunologist Admitted He Had More Antibodies Than the Vaccinated — His Religious Accommodation Was Denied Anyway Kupper had natural immunity; his immunologist confirmed he had more antibodies than someone with both shots. Every single religious accommodation filed was denied. ──────────────────────────────────────── [00:50:00] Kupper Was Given Separation Papers Three Weeks Before His 19-Year Mark — One Year Short of a Full Retirement A class-wide court injunction from attorney Aaron Siri covered Kupper the day after his separation papers arrived — but thousands of others had no such protection. ──────────────────────────────────────── [01:02:00] $6 Billion Was Already Appropriated to These Service Members — the Military Used It for Something Else When It Kicked Them Out Kupper: every dollar was authorized in the NDAA but never spent on the personnel allocated — it could be repaid to the 8,000 dismissed without any new appropriation. ──────────────────────────────────────── [01:12:00] A Technical Sergeant With Both Shots Died of Heart Failure in His Early 30s — the Air Force Stopped Updating Its COVID Death Tracker That Day The Air Force had listed 16 COVID deaths noting none were vaccinated — the day this man died with both shots on record, they stopped updating the tracker. ──────────────────────────────────────── [01:22:00] 'Duty to Disobey' Documentary Releases in AMC Theaters June 30 — dutytodisobeyfilm.com Children's Health Defense produced this with service members from multiple branches; Ron Johnson appears alongside those kicked out for refusing the unlawful emergency use mandate. ──────────────────────────────────────── [01:38:00] Dr. Michael Guillén: 95% of the Universe Is Invisible — Modern Cosmology Has Been in Crisis Since Hubble's Discovery in 1929 Dark matter and dark energy are completely unknown. The steady-state model was destroyed by Hubble's discovery that the universe is expanding — the crisis has deepened since. ──────────────────────────────────────── [01:55:00] Guillén: From Atheist to Christian Through Science — the Universe Had to Hit the Jackpot a Million Times at Every Level for Us to Exist The anthropic principle: from the quantum level to the cosmic web, everything was calibrated precisely for life — either infinite accidents or one designer. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

──────────────────────────────────────── [00:05:00] Hegseth Quotes Psalm 144 as God's Blessing for War — Knight: David Prayed Before Every Battle and Never Assumed God Was With Him David used the Urim and Thummim to ask God's will before war. Hegseth has no such instrument and no declaration of war from God or Congress. ──────────────────────────────────────── [00:15:00] Dispensationalism's Core Error: Treating the Shadow as Greater Than the Reality It Points To Knight: Hebrews was written to people returning to the shadow of Judaism rather than the substance in Christ — Hegseth and Huckabee are the Judaizers of Galatians, replacing Christ with a political state. ──────────────────────────────────────── [00:28:00] Nick Kupper: The COVID Shot Was Never Legally Approved — Pfizer Didn't Manufacture an Approved Version Until January 2022 DOD admitted in Kupper's lawsuit that nothing was fully approved until June 2022 — by which time the Air Force had already kicked people out for the unlawfully mandated product. ──────────────────────────────────────── [00:38:00] Kupper's Base Immunologist Admitted He Had More Antibodies Than the Vaccinated — His Religious Accommodation Was Denied Anyway Kupper had natural immunity; his immunologist confirmed he had more antibodies than someone with both shots. Every single religious accommodation filed was denied. ──────────────────────────────────────── [00:50:00] Kupper Was Given Separation Papers Three Weeks Before His 19-Year Mark — One Year Short of a Full Retirement A class-wide court injunction from attorney Aaron Siri covered Kupper the day after his separation papers arrived — but thousands of others had no such protection. ──────────────────────────────────────── [01:02:00] $6 Billion Was Already Appropriated to These Service Members — the Military Used It for Something Else When It Kicked Them Out Kupper: every dollar was authorized in the NDAA but never spent on the personnel allocated — it could be repaid to the 8,000 dismissed without any new appropriation. ──────────────────────────────────────── [01:12:00] A Technical Sergeant With Both Shots Died of Heart Failure in His Early 30s — the Air Force Stopped Updating Its COVID Death Tracker That Day The Air Force had listed 16 COVID deaths noting none were vaccinated — the day this man died with both shots on record, they stopped updating the tracker. ──────────────────────────────────────── [01:22:00] 'Duty to Disobey' Documentary Releases in AMC Theaters June 30 — dutytodisobeyfilm.com Children's Health Defense produced this with service members from multiple branches; Ron Johnson appears alongside those kicked out for refusing the unlawful emergency use mandate. ──────────────────────────────────────── [01:38:00] Dr. Michael Guillén: 95% of the Universe Is Invisible — Modern Cosmology Has Been in Crisis Since Hubble's Discovery in 1929 Dark matter and dark energy are completely unknown. The steady-state model was destroyed by Hubble's discovery that the universe is expanding — the crisis has deepened since. ──────────────────────────────────────── [01:55:00] Guillén: From Atheist to Christian Through Science — the Universe Had to Hit the Jackpot a Million Times at Every Level for Us to Exist The anthropic principle: from the quantum level to the cosmic web, everything was calibrated precisely for life — either infinite accidents or one designer. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

With Johann Bauersachs, Hannover Medical School, Hannover - Germany and Samira Soltani, Hannover Medical School, Hannover - Germany. Link to European Heart Journal paper Link to European Heart Journal editorial

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Harriette Van Spall from Hamilton, Ontario, Canada. They discuss her team's comprehensive review paper all about the intersection of heart failure with the preserved ejection fraction and atrial fibrillation. In particular, they cover the diagnostic challenges in this patient group, established and emerging medications, and the potential for conduction system pacing as a treatment option. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks!   Link to published paper: https://heart.bmj.com/content/early/2026/03/06/heartjnl-2025-326954

“The Fitness Industry Is Lying To You (Here's The Truth)”What if the biggest problem in modern fitness… isn't motivation? What if it's misinformation? In this powerful conversation on the Live From America Podcast, Coach Alex VanHouten joins Hatem for a deep dive into the psychology, biology, and spiritual side of health and fitness.Together, they unpack:Why the fitness industry keeps failing everyday peopleThe difference between looking fit vs. actually being healthyHow exercise changes your brain chemistry and mindsetWhy belief systems affect physical performanceThe science behind resilience, discipline, and “grit”How visualization improves athletic and mental performanceWhy community matters for transformationThe hidden connection between physical fitness and emotional healthWhat elite operators understand about mindset that most people don'tCoach Alex also shares his personal story of living with a painful genetic disorder and how it shaped his understanding of stewardship, suffering, and discipline.Meanwhile, Hatem shares the incredible story of surviving heart failure, living with an LVAD, undergoing a heart transplant, and rebuilding his life through fitness and mental resilience.This episode is not about six-week transformations.It's about becoming the kind of person who refuses to quit.⏱️ Timestamp Outline00:00 – Intro: Why Health & Resilience Matter01:15 – What Is Exercise Science?03:00 – The Fitness Industry's Biggest Lie05:00 – Why “Quick Fixes” Fail08:00 – Alex's Genetic Disorder & Pain Journey11:00 – Hatem's Heart Failure & Heart Transplant Story14:30 – Why Fitness Saved Hatem's Life15:30 – Bio-Individuality Explained18:30 – Looking Fit vs Actually Being Healthy21:45 – Where Everyday People Should Start24:00 – Why 1% Better Daily Works27:00 – How Health Impacts Relationships & Identity29:00 – Injury, Illness & Recovery Mindset31:00 – The “Lone Wolf Problem”34:00 – Agency: Life Happening TO You vs THROUGH You37:00 – Why Community Changes Everything40:00 – Exercise, Hope Molecules & Mental Health44:00 – Motivation vs Discipline48:00 – Visualization & Athletic Performance52:00 – Grit, Mental Toughness & The Will To Live58:00 – Everyday Spy & Operator Training1:00:00 – Faithful Fitness & Why Alex Wrote The Book1:05:00 – Final Encouragement + Closing

In this episode, Jeffrey Farber, MD, President & CEO of The New Jewish Home, discusses the organization's accredited heart failure program within a skilled nursing facility setting. He shares how specialized cardiac rehabilitation, interdisciplinary care, and close partnerships with academic medical centers are helping medically complex older adults recover safely and regain quality of life after hospitalization.

Are you aware of the latest information on the management of cardiovascular-kidney-metabolic (CKM) syndrome? Hear our expert faculty discuss! Credit available for this activity expires: 5/19/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/addressing-intersection-between-heart-failure-and-kidney-2026a1000fj1?ecd=bdc_podcast_libsyn_mscpedu

Join Liz Cruz M.D. and Tina Nunziato, Certified Holistic Nutrition Consultant, as they discuss a study that was presented at a recent American Heart Association conference.  Learn about the potential connection between long-term melatonin use and heart failure.  Find out the right dosage for adults and children and what to look out for in melatonin supplements.  Discover other strategies, aside from the popular supplement for better sleep.  Watch us on YouTube:   https://youtu.be/cN8ahsaXC8oDr. Cruz is a Board Certified Gastroenterologist who practices in Phoenix, AZ. Along with her wife Tina Nunziato, a Certified Holistic Nutritionist, they have helped tens of thousands of individuals get well from a more holistic standpoint. They focus on issues such as constipation, diarrhea, acid reflux, heartburn, gas, bloating, food sensitivities, IBS, Crohn's disease, and diverticulitis in addition to a person's general overall health. They do this by teaching about real food, water, digestive enzymes, probiotics, detox, greens, electrolytes, food sensitivity testing, and so much more. If you're struggling with finding the answers to your issues, tired of not feeling well, and sick of taking over the counter and prescription medicines, schedule a FREE 30 minute phone consult at www.drlizcruz.com.

SEASON 4 EPISODE 84: COUNTDOWN WITH KEITH OLBERMANN A-Block (3:00) SPECIAL COMMENT: Back from a week off just in time to put the podcast on health hiatus...details within today's supersized edition. Plus, befitting the time off, some meta pictures on how Democrats should plan for what they want this country to look like on its 300th anniversary, if it lasts that long. Will we have jailed Trump and gotten back the money he took? Undone his damage? Eliminated the anachronistic idea that Wyoming should have as many senators as California? Let the Supreme Court continue to lie, cheat and steal the democracy from under us? As John Candy said in "Splash": Think big, be big, my friend. MORE IMMEDIATELY: Whaddya mean the Governor of Virginia hasn't been BRIEFED on the way to overturn her state's Supreme Court's usurpation of redistricting? Why the hell not Hakeem Jeffries? Anybody notice Trump is simply rotating the same three lies about Iran? Why are only independent journalists like Garrett Graff still covering the WHCD non-shooting when the New York Times is doing 31 paragraphs on the future of the dinner like anybody gave a crap? AND MOST IMPORTANTLY: stop saying Trump is painting everything GOLD. That color is not GOLD. It is the color of WEE WEE. Say it. Use the clinical terms, use the gutter terms. The gutter terms define this idiot president. Stop saying gold when you mean whizzzzzzzzzzzzzz. B-Block (56:00) ON THE PASSING OF TED TURNER: Hard to believe few of the obituaries mentioned how he also invented 7-day-a-week sports on national television. Or how Jane Fonda kept him from destroying himself in, like, 1982. One particularly harrowing saga had him telling the lowest ranking staffer at CNN's Washington Bureau which way, when he finally decided he'd do it, he'd do it. And this is said with admiration and affection for the man who created the place where I and so many of the figures of the last 45 years began our TV careers. C-Block (1:30:00) ALL TED ALL THE TIME: I was holding back until I was certain I wouldn't jinx him. My beloved first rescue dog, Ted, was up against it last fall. I took him to the University of Florida for life-saving open heart surgery and boy, did they! Eight hours on the table, eight hours of SICU, all for an eight pound dog and now - he's not even on any medications! It's a long story and I would insist it's worth hearing it. And if you have a dog (or know of one) moving from Mitral Valve Disease to Heart Failure, maybe this will provide you with hope - and an option.See omnystudio.com/listener for privacy information.

What if one of the most common escalation strategies for acute heart failure doesn't actually improve outcomes? Internal medicine physicians Benjamin P. Geisler, Jeffrey L. Greenwald, and Kathy May Tran, editors of 50 Studies Every Hospitalist Should Know, join the show to break down what the DOSE trial really tells us about managing diuretics on the wards. Based on their KevinMD article "Managing acute heart failure: evidence from the DOSE trial," they explain why continuous furosemide infusions showed no clinical advantage over intermittent boluses for decongestion, and what that means for your daily practice. You will hear how headline-driven medicine can mislead clinicians, why knowing who was excluded from a trial matters as much as the results, and how evidence-based medicine teaching is evolving in the age of AI. Whether you are a hospitalist, a trainee on the wards, or a primary care physician managing heart failure transitions, this episode will sharpen how you read and apply the studies that shape patient care. Tune into our episode "2026 Cholesterol Guidelines: LDL goals, lipoprotein(a), and coronary calcium scoring," brought to you by Novartis Pharmaceuticals Corporation. For the first time in eight years, LDL cholesterol goals have changed, and preventive cardiologist Seth Baum says the new guidelines are a long-overdue course correction. He breaks down the new LDL targets for your highest-risk patients, why the LDL hypothesis should be retired in favor of the LDL fact, why lipoprotein(a) screening finally belongs in every patient's workup, what a coronary calcium score over 300 really means for how aggressively you treat, and how to talk to statin-skeptical patients without losing their trust. Listen now at KevinMD.com/cholesterol. VISIT SPONSOR → https://kevinmd.com/cholesterol Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

From surviving two strokes, heart failure, and a life-saving transplant to producing a powerful PBS documentary series, Jonathan Scott Bognar shares a raw and inspiring story of resilience, reinvention, and purpose. In this episode, Jonathan opens up about losing his ability to speak due to aphasia, rebuilding his career from the ground up, and how he transitioned from Hollywood film production into meaningful storytelling that educates and serves others. https://www.youtube.com/watch?v=Cg8iomv10Wk We dive into his upcoming documentary Alive But Not Well, which explores major diseases affecting people as they age through the lens of patients, caregivers, doctors, and advocates. Jonathan explains how his own health journey sparked the idea, and why caregiving is one of the most overlooked yet universal human experiences. He also breaks down his philosophy of “rigorous optimism” and “rugged flexibility,” showing how mindset, persistence, and adaptability are critical not just in business but in surviving life itself. If you've ever faced adversity, struggled with reinvention, or wondered how to turn pain into purpose, this conversation will challenge you to rethink your limits and remind you to “die with memories, not dreams.” Quotes: “Everything in life is about how you view what's happening to you—you have to choose a positive attitude, even when it's hard.”  “In order to succeed, you have to be rigid in your commitment but flexible in your approach—that's where real progress happens.”  “Rigorous optimism means you don't always feel positive—you fight to be positive anyway.” Contact Details: Jonathan Scott Bogner Official Website

In this episode, Pranav Loyalka, MD - Cardiologist, HCA Houston Heart Medical Center, Medical Director of Structural Heart Disease, Heart Failure, Heart Transplant and Mechanical Circulatory Support, HCA Gulf Coast Division, discusses major advancements like transcatheter valve replacement and the evolving role of AI in cardiac care. He also shares insights on training the next generation of cardiologists, balancing specialization, and addressing gaps in access to care.

Heart failure (HF) affects more than 64 million individuals worldwide, and 20% to 30% of patients with HF and systolic dysfunction have cardiac dyssynchrony due to conduction system disease. JAMA Review author Mihail Chelu, MD, PhD, of Baylor College of Medicine discusses cardiac resynchronization therapy with JAMA Associate Editor David Simel, MD, MHS. Related Content: Cardiac Resynchronization Therapy Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure

If you're managing patients with heart failure, you already know the medication landscape has evolved quickly over the past decade. From traditional volume management with furosemide to newer, guideline-driven therapies like sacubitril/valsartan and empagliflozin, staying up to date is essential—but not always easy. In this episode, we break down three cornerstone medication classes you'll encounter every day in practice: loop diuretics, ARNI therapy, and SGLT2 inhibitors. We start with the fundamentals of loop diuretics—how they work, when to use them, and key monitoring parameters—before shifting into the mortality-reducing benefits of ARNI therapy. Finally, we explore the rapidly expanding role of SGLT2 inhibitors, which have transformed both heart failure and chronic kidney disease management. Whether you're a pharmacist, nurse, or student, this episode focuses on practical, real-world application. We highlight clinical pearls, common pitfalls, and monitoring strategies to help you feel more confident when optimizing therapy. Tune in to sharpen your understanding of these essential therapies and walk away with actionable insights you can use right away in patient care. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101